Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient

Bortezomib, an inhibitor of 26S proteosome, is recently approved treatment option for multiple myeloma. Thalidomide, a drug with immunomodulating and antiangiogenic effects, has also shown promise as an effective treatment in multiple myeloma. Pulmonary complications are believed to be rare, especia...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Wonseok, Kim, Jin Seok, Cho, Sang Ho, Kim, Sung Kyu, Chang, Joon, Park, Moo Suk
Formato: Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852803/
https://www.ncbi.nlm.nih.gov/pubmed/20376900
http://dx.doi.org/10.3349/ymj.2010.51.3.448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852803/
https://www.ncbi.nlm.nih.gov/pubmed/20376900
http://dx.doi.org/10.3349/ymj.2010.51.3.448

Ejemplares similares